Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Ocular Therapeutix™ to Present at October Ophthalmology Meetings
-
ProKidney to Participate in the UBS Virtual Organ Restoration Day
-
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
-
Vanqua Bio Announces Positive Interim Results from Phase 1 Clinical Trial of VQ-101, an Orally Administered, Brain-Penetrant, Allosteric Activator of GCase for the Treatment of GBA-Parkinson’s and R
-
BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS™ Systems in Taiwan and South Korea
-
BullFrog AI Announces Publication of Data Supporting Potential of Liver Disease Treatment Candidate BF-114
-
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
-
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
-
Reunion Neuroscience Partners with Seleni Institute on Effective Diagnosis and Treatment of Maternal Mental Health Disorders
-
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
-
Chiesi USA Releases 2023 Sustainability Report and Highlights US Community Engagement Strategy Focus Areas
-
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases
-
ROCKWOOL A/S – transactions in connection with share buy-back programme
-
Alliance Trust PLC - Net Asset Value
-
Howard Hughes Holdings Inc. Announces Dates and Times for 2024 Third Quarter Earnings Release and Conference Call
-
Springbig Launches Innovative MP5 Messaging Feature with Remarkable Beta Test Results
-
CORRECTION: AS Tallinna Sadam operational volumes for 2024 Q3 and 9 months
-
Panavance Therapeutics Provides Update on Phase 1 Clinical Trial of Misetionamide in Pancreatic Cancer at 2024 Visceral Medicine Congress
-
Xypher.io’s Comprehensive Crypto Alert System to Empower Traders with Real-Time Insights
-
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
-
Boosty Labs Celebrates 7 Years of Development Leadership
-
Calvetti Ferguson Adds Assurance Partner to Growing Nashville Office
-
Stallion Uranium Signs Binding LOI for up to $2.2M for Horse Heaven Gold and Antimony Project
-
Bird Construction Announces 50% Dividend Increase and Releases 2025-2027 Financial Targets
-
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
-
MADD Canada and KAG Canada Honour Alberta Victim in Road Safety Campaign
-
Evergold Awaits New Drill Assays from DEM Porphyry “Halo”, Identifies Likely Location of Intrusive Centre
-
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
-
Survey Reveals that Half of U.S. Enterprises Have Immature External Attack Surface Management Programs Despite 90% Indicating Increases in Impactful Incidents
-
Pillar Security’s State of Attacks on GenAI: 90% of Successful Attacks Seen in the Wild Resulted in Leaked Sensitive Data
-
Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology
-
Net3.org Launches Beacon Network for Privacy-Enhanced Communications
-
SemiCab Wins Major New Contract with $10 Billion Indian Consumer Packaged Goods Company for New Pilot in India
-
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
-
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
-
OTC Markets Group Welcomes SulNOx Group Plc to OTCQX
-
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
-
Stella-Jones Will Hold a Conference Call to Discuss its Third Quarter Results
-
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
-
Marex Agrees Terms to Acquire UK FX Specialist Hamilton Court Group
-
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
-
YieldMax™ ETFs Announces Distributions on BABO (69.59%), MRNY (61.51%), FBY (58.57%), YMAX (60.44%), YMAG (76.46%) and Others
-
HSBC Bank Plc - Form 8.5 (EPT/RI) - Keywords Studios plc
-
HSBC Bank Plc - Form 8.5 (EPT/RI) - Learning Technologies Group plc
-
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
-
Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes
-
Nova Minerals Announces 41m @ 4.6 g/t Au from Surface at the RPM deposit on its Estelle Gold-Antimony Project, in Alaska
-
Fixing of coupon rates - Nykredit Realkredit A/S
-
CORRECTION -- Safer-Sidewalks Introduces Effective Sidewalk Repair Services to Boost Public Safety in Los Angeles
-
Notification of Share Transaction
